Medicare Program; Application by The Compliance Team (TCT) for Continued CMS Approval of its Home Infusion Therapy (HIT) Accreditation Program, 33354-33356 [2024-09172]
Download as PDF
33354
Federal Register / Vol. 89, No. 83 / Monday, April 29, 2024 / Notices
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov, suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov. Written
public comments submitted up to 72
hours prior to the ACD meeting will be
provided to ACD members before the
meeting. Written comments received in
advance of the meeting will be included
in the official record of the meeting.
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–09090 Filed 4–26–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
FOR FURTHER INFORMATION CONTACT:
[Docket No. CDC–2024–0034]
Meeting of the Advisory Committee to
the Director (ACD), Centers for Disease
Control and Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Advisory
Committee to the Director, Centers for
Disease Control and Prevention (ACD,
CDC). This meeting is open to the
public. The meeting will be webcast live
via the World Wide Web.
DATES: The meeting will be held on June
6, 2024, from 10 a.m. to 3 p.m., EDT
(times subject to change).
The public may submit written
comments from April 29, 2024 through
May 24, 2024.
ADDRESSES: No registration is required
to view the meeting via the World Wide
Web. Information for accessing the
webcast will be available at https://
www.cdc.gov/about/advisorycommittee-director/.
Written comments: You may submit
comments identified by Docket No.
CDC–2024–0034 by either of the
following methods below. Do not
submit comments for the docket by
email. CDC does not accept comments
for the docket by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Tiffany Brown, JD MPH,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop H21–10, Atlanta, Georgia
30329–4027. Attn: Docket number CDC–
2024–0034.
Instructions: All submissions received
must include the Agency name and
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:54 Apr 26, 2024
Jkt 262001
Tiffany Brown, JD MPH, Centers for
Disease Control and Prevention, Office
of the Chief of Staff, 1600 Clifton Road
NE, Mailstop H21–10, Atlanta, Georgia
30329–4027, Telephone: (404) 498–
6655; Email Address: ACDirector@
cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to
the Director, CDC, shall (1) make
recommendations to the Director
regarding ways to prioritize the
activities of the agency in alignment
with the CDC Strategic Plan required
under section 305(c); H.R. 2617–1252;
(2) advise on ways to achieve or
improve performance metrics in relation
to the CDC Strategic Plan, and other
relevant metrics, as appropriate; (3)
provide advice and recommendations
on the development of the Strategic
Plan, and any subsequent updates, as
appropriate; (4) advise on grant,
cooperative agreements, contracts, or
other transactions, as applicable; (5)
provide other advice to the Director, as
requested, to fulfill duties under
sections 301 and 311; and (6) appoint
subcommittees. The committee
recommends ways to prioritize CDC’s
activities, improve results, and address
health disparities. It also provides
guidance to help CDC work more
effectively with its various private and
public sector constituents to make
health protection a practical reality.
Matters to be Considered: The agenda
will include an update on CDC
priorities from the CDC Director,
discussions on CDC’s work to address
equity and social determinants of
health, lab readiness and response
improvement efforts, programmatic
updates, and updates from the ACD
Data and Surveillance Workgroup and
the Communications and Public
Engagement Workgroup. Agenda items
are subject to change as priorities
dictate.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on April 29, 2024 through
May 24, 2024.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–09081 Filed 4–26–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3462–PN]
Medicare Program; Application by The
Compliance Team (TCT) for Continued
CMS Approval of its Home Infusion
Therapy (HIT) Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice with request for
comment.
AGENCY:
E:\FR\FM\29APN1.SGM
29APN1
Federal Register / Vol. 89, No. 83 / Monday, April 29, 2024 / Notices
This notice acknowledges the
receipt of an application from The
Compliance Team (TCT) for continued
approval by the Centers for Medicare &
Medicaid Services (CMS) of TCT’s
national accrediting organization
program for suppliers providing home
infusion therapy (HIT) services and that
wish to participate in the Medicare or
Medicaid programs. The statute requires
that within 60 days of receipt of an
organization’s complete application,
CMS will publish a notice that identifies
the national accrediting body making
the request, describes the nature of the
request, and provides at least a 30-day
public comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, by May
29, 2024.
ADDRESSES: In commenting, refer to file
code CMS–3462–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3462–PN, P.O. Box 8016,
Baltimore, MD 21244–8010.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3462–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Shannon Freeland, (410) 786–4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:54 Apr 26, 2024
Jkt 262001
public comments. CMS will not post on
Regulations.gov public comments that
make threats to individuals or
institutions or suggest that the
commenter will take actions to harm
individual. CMS continues to encourage
individuals not to submit duplicative
comments. We will post acceptable
comments from multiple unique
commenters even if the content is
identical or nearly identical to other
comments.
I. Background
Home infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted December 13, 2016) added
section 1861(iii) to the Social Security
Act (the Act), establishing a new
Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines
‘‘home infusion therapy’’ as professional
services, including nursing services;
training and education not otherwise
covered under the Durable Medical
Equipment (DME) benefit; remote
monitoring; and other monitoring
services. HIT must be furnished by a
qualified HIT supplier and furnished in
the individual’s home. The individual
must:
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
designated AOs. These statutory factors
are as follows:
• The ability of the organization to
conduct timely reviews of accreditation
applications.
• The ability of the organization to
take into account the capacities of
suppliers located in a rural area (as
defined in section 1886(d)(2)(D) of the
Act).
• Whether the organization has
established reasonable fees to be
charged to suppliers applying for
accreditation.
• Such other factors as the Secretary
determines appropriate.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
33355
Section 1834(u)(5)(B) of the Act
requires the Secretary to designate AOs
to accredit HIT suppliers furnishing HIT
no later than January 1, 2021. Section
1861(iii)(3)(D)(i)(III) of the Act requires
a ‘‘qualified home infusion therapy
supplier’’ to be accredited by a CMSapproved AO, pursuant to section
1834(u)(5) of the Act.
On March 1, 2019, we published a
solicitation notice entitled, ‘‘Medicare
Program; Solicitation of Independent
Accrediting Organizations to Participate
in the Home Infusion Therapy Supplier
Accreditation Program’’ (84 FR 7057).
This notice informed national AOs that
accredit HIT suppliers of an opportunity
to submit applications to participate in
the HIT supplier accreditation program.
We stated that complete applications
would be considered for the January 1,
2021 designation deadline if received by
February 1, 2020. Regulations for the
approval and oversight of AOs for HIT
organizations are located at 42 CFR part
488, subpart L. The requirements for
HIT suppliers are located at 42 CFR part
486, subpart I.
II. Approval of Deeming Organization
Section 1834(u)(5) of the Act and
regulations at 42 CFR 488.1010 require
that our findings concerning review and
approval of a national accrediting
organization’s requirements consider,
among other factors, the applying
accrediting organization’s requirements
for accreditation; survey procedures;
resources for conducting required
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide CMS with the
necessary data.
Our rules at 42 CFR 488.1020(a)
require that we publish, after receipt of
an organization’s complete application,
a notice that identifies the national
accrediting body making the request,
describes the nature of the request, and
provides at least a 30-day public
comment period. Pursuant to our rules
at 42 CFR 488.1010(d), we have 210
days from the receipt of a complete
application to publish notice of
approval or denial of the application.
The purpose of this proposed notice
is to inform the public of The
Compliance Team’s (TCT’s) request for
CMS’ continued recognition of its HIT
accreditation program. This notice also
solicits public comment on whether
TCT’s requirements meet or exceed the
Medicare requirements of participation
for HIT services.
E:\FR\FM\29APN1.SGM
29APN1
33356
Federal Register / Vol. 89, No. 83 / Monday, April 29, 2024 / Notices
III. Evaluation of Deeming Authority
Request
khammond on DSKJM1Z7X2PROD with NOTICES
In the September 23, 2019 Federal
Register, we published TCT’s initial
application for recognition as an
accreditation organization for HIT (84
FR 49736). On September 28, 2020, we
published notification of their approval
as such an organization, effective
October 1, 2020 through October 1, 2024
(85 FR 60799). TCT has since submitted
all the necessary materials to enable us
to make a determination concerning its
request for continued recognition of its
HIT accreditation program. This
application was determined to be
complete on March 2, 2024. Under
section 1834(u)(5) of the Act and 42 CFR
488.1010 (Application and reapplication procedures for national
home infusion therapy accrediting
organizations), our review and
evaluation of TCT will be conducted in
accordance with, but not necessarily
limited to, the following factors:
• The equivalency of TCT’s standards
for HIT as compared with CMS’ HIT
requirements for participation in the
Medicare program.
• TCT’s survey process to determine
the following:
++ The composition of the survey
team, surveyor qualifications, and the
ability of the organization to provide
continuing surveyor training.
++ The comparability of TCT’s to
CMS’ standards and processes,
including survey frequency, and the
ability to investigate and respond
appropriately to complaints against
accredited facilities.
++ TCT’s processes and procedures
for monitoring a HIT supplier found out
of compliance with TCT’s program
requirements.
++ TCT’s capacity to report
deficiencies to the surveyed facilities
and respond to the facility’s plan of
correction in a timely manner.
++ TCT’s capacity to provide CMS
with electronic data and reports
necessary for effective assessment and
interpretation of the organization’s
survey process.
++ The adequacy of TCT’s staff and
other resources, and its financial
viability.
++ TCT’s capacity to adequately fund
required surveys.
++ TCT’s policies with respect to
whether surveys are announced or
unannounced, to ensure that surveys are
unannounced.
++ TCT’s agreement to provide CMS
with a copy of the most current
accreditation survey together with any
other information related to the survey
as CMS may require (including
corrective action plans).
++ TCT’s policies and procedures to
avoid conflicts of interest, including the
appearance of conflicts of interest,
involving individuals who conduct
surveys, audits or participate in
accreditation decisions.
++ TCT’s agreement or policies for
voluntary and involuntary termination
of HIT suppliers.
++ TCT’s agreement or policies for
voluntary and involuntary termination
of the HIT AO program.
IV. Collection of Information
Requirements
respond to the comments in the
preamble to that document.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Trenesha Fultz-Mimms, who
is the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2024–09172 Filed 4–26–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–9148–N]
Medicare and Medicaid Programs;
Quarterly Listing of Program
Issuances—January through March
2024
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This document does not impose
information collection requirements,
that is, reporting, recordkeeping, or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public
comments, we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble, and, when we proceed
with a subsequent document, we will
This quarterly notice lists
CMS manual instructions, substantive
and interpretive regulations, and other
Federal Register notices that were
published in the 3-month period,
relating to the Medicare and Medicaid
programs and other programs
administered by CMS.
FOR FURTHER INFORMATION CONTACT: It is
possible that an interested party may
need specific information and not be
able to determine from the listed
information whether the issuance or
regulation would fulfill that need.
Consequently, we are providing contact
persons to answer general questions
concerning each of the addenda
published in this notice.
SUMMARY:
Addenda
Contact
I CMS Manual Instructions ......................................................................................................
II Regulation Documents Published in the Federal Register .................................................
III CMS Rulings ........................................................................................................................
IV Medicare National Coverage Determinations .....................................................................
V FDA-Approved Category B IDEs .........................................................................................
VI Collections of Information ....................................................................................................
VII Medicare—Approved Carotid Stent Facilities ....................................................................
VIII American College of Cardiology-National Cardiovascular Data Registry Sites ...............
IX Medicare’s Active Coverage-Related Guidance Documents ..............................................
X One-time Notices Regarding National Coverage Provisions ...............................................
XI National Oncologic Positron Emission Tomography Registry Sites ...................................
XII Medicare—Approved Ventricular Assist Device (Destination Therapy) Facilities .............
XIII Medicare—Approved Lung Volume Reduction Surgery Facilities ....................................
XIV Medicare—Approved Bariatric Surgery Facilities .............................................................
Ismael Torres ..........................
Terri Plumb .............................
Tiffany Lafferty ........................
Wanda Belle, MPA .................
John Manlove .........................
William Parham .......................
Sarah Fulton, MHS .................
Sarah Fulton, MHS .................
Lori Ashby, MA .......................
JoAnna Baldwin, MS ..............
David Dolan, MBA ..................
David Dolan, MBA ..................
Sarah Fulton, MHS .................
Sarah Fulton, MHS .................
VerDate Sep<11>2014
20:54 Apr 26, 2024
Jkt 262001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
E:\FR\FM\29APN1.SGM
29APN1
Phone No.
(410) 786–1864
(410) 786–4481
(410)786–7548
(410) 786–7491
(410) 786–6877
(410) 786–4669
(410) 786–2749
(410) 786–2749
(410) 786–6322
(410) 786–7205
(410) 786–3365
(410) 786–3365
(410) 786–2749
(410) 786–2749
Agencies
[Federal Register Volume 89, Number 83 (Monday, April 29, 2024)]
[Notices]
[Pages 33354-33356]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09172]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3462-PN]
Medicare Program; Application by The Compliance Team (TCT) for
Continued CMS Approval of its Home Infusion Therapy (HIT) Accreditation
Program
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice with request for comment.
-----------------------------------------------------------------------
[[Page 33355]]
SUMMARY: This notice acknowledges the receipt of an application from
The Compliance Team (TCT) for continued approval by the Centers for
Medicare & Medicaid Services (CMS) of TCT's national accrediting
organization program for suppliers providing home infusion therapy
(HIT) services and that wish to participate in the Medicare or Medicaid
programs. The statute requires that within 60 days of receipt of an
organization's complete application, CMS will publish a notice that
identifies the national accrediting body making the request, describes
the nature of the request, and provides at least a 30-day public
comment period.
DATES: To be assured consideration, comments must be received at one of
the addresses provided below, by May 29, 2024.
ADDRESSES: In commenting, refer to file code CMS-3462-PN.
Comments, including mass comment submissions, must be submitted in
one of the following three ways (please choose only one of the ways
listed):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the ``Submit a
comment'' instructions.
2. By regular mail. You may mail written comments to the following
address ONLY: Centers for Medicare & Medicaid Services, Department of
Health and Human Services, Attention: CMS-3462-PN, P.O. Box 8016,
Baltimore, MD 21244-8010.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments to
the following address ONLY: Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Attention: CMS-3462-PN, Mail
Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
For information on viewing public comments, see the beginning of
the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Shannon Freeland, (410) 786-4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following
website as soon as possible after they have been received: https://www.regulations.gov. Follow the search instructions on that website to
view public comments. CMS will not post on Regulations.gov public
comments that make threats to individuals or institutions or suggest
that the commenter will take actions to harm individual. CMS continues
to encourage individuals not to submit duplicative comments. We will
post acceptable comments from multiple unique commenters even if the
content is identical or nearly identical to other comments.
I. Background
Home infusion therapy (HIT) is a treatment option for Medicare
beneficiaries with a wide range of acute and chronic conditions.
Section 5012 of the 21st Century Cures Act (Pub. L. 114-255, enacted
December 13, 2016) added section 1861(iii) to the Social Security Act
(the Act), establishing a new Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines ``home infusion therapy'' as
professional services, including nursing services; training and
education not otherwise covered under the Durable Medical Equipment
(DME) benefit; remote monitoring; and other monitoring services. HIT
must be furnished by a qualified HIT supplier and furnished in the
individual's home. The individual must:
Be under the care of an applicable provider (that is,
physician, nurse practitioner, or physician assistant); and
Have a plan of care established and periodically reviewed
by a physician in coordination with the furnishing of home infusion
drugs under Part B, that prescribes the type, amount, and duration of
infusion therapy services that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act requires that a
qualified HIT supplier be accredited by an accrediting organization
(AO) designated by the Secretary in accordance with section 1834(u)(5)
of the Act. Section 1834(u)(5)(A) of the Act identifies factors for
designating AOs and in reviewing and modifying the list of designated
AOs. These statutory factors are as follows:
The ability of the organization to conduct timely reviews
of accreditation applications.
The ability of the organization to take into account the
capacities of suppliers located in a rural area (as defined in section
1886(d)(2)(D) of the Act).
Whether the organization has established reasonable fees
to be charged to suppliers applying for accreditation.
Such other factors as the Secretary determines
appropriate.
Section 1834(u)(5)(B) of the Act requires the Secretary to
designate AOs to accredit HIT suppliers furnishing HIT no later than
January 1, 2021. Section 1861(iii)(3)(D)(i)(III) of the Act requires a
``qualified home infusion therapy supplier'' to be accredited by a CMS-
approved AO, pursuant to section 1834(u)(5) of the Act.
On March 1, 2019, we published a solicitation notice entitled,
``Medicare Program; Solicitation of Independent Accrediting
Organizations to Participate in the Home Infusion Therapy Supplier
Accreditation Program'' (84 FR 7057). This notice informed national AOs
that accredit HIT suppliers of an opportunity to submit applications to
participate in the HIT supplier accreditation program. We stated that
complete applications would be considered for the January 1, 2021
designation deadline if received by February 1, 2020. Regulations for
the approval and oversight of AOs for HIT organizations are located at
42 CFR part 488, subpart L. The requirements for HIT suppliers are
located at 42 CFR part 486, subpart I.
II. Approval of Deeming Organization
Section 1834(u)(5) of the Act and regulations at 42 CFR 488.1010
require that our findings concerning review and approval of a national
accrediting organization's requirements consider, among other factors,
the applying accrediting organization's requirements for accreditation;
survey procedures; resources for conducting required surveys; capacity
to furnish information for use in enforcement activities; monitoring
procedures for provider entities found not in compliance with the
conditions or requirements; and ability to provide CMS with the
necessary data.
Our rules at 42 CFR 488.1020(a) require that we publish, after
receipt of an organization's complete application, a notice that
identifies the national accrediting body making the request, describes
the nature of the request, and provides at least a 30-day public
comment period. Pursuant to our rules at 42 CFR 488.1010(d), we have
210 days from the receipt of a complete application to publish notice
of approval or denial of the application.
The purpose of this proposed notice is to inform the public of The
Compliance Team's (TCT's) request for CMS' continued recognition of its
HIT accreditation program. This notice also solicits public comment on
whether TCT's requirements meet or exceed the Medicare requirements of
participation for HIT services.
[[Page 33356]]
III. Evaluation of Deeming Authority Request
In the September 23, 2019 Federal Register, we published TCT's
initial application for recognition as an accreditation organization
for HIT (84 FR 49736). On September 28, 2020, we published notification
of their approval as such an organization, effective October 1, 2020
through October 1, 2024 (85 FR 60799). TCT has since submitted all the
necessary materials to enable us to make a determination concerning its
request for continued recognition of its HIT accreditation program.
This application was determined to be complete on March 2, 2024. Under
section 1834(u)(5) of the Act and 42 CFR 488.1010 (Application and re-
application procedures for national home infusion therapy accrediting
organizations), our review and evaluation of TCT will be conducted in
accordance with, but not necessarily limited to, the following factors:
The equivalency of TCT's standards for HIT as compared
with CMS' HIT requirements for participation in the Medicare program.
TCT's survey process to determine the following:
++ The composition of the survey team, surveyor qualifications, and
the ability of the organization to provide continuing surveyor
training.
++ The comparability of TCT's to CMS' standards and processes,
including survey frequency, and the ability to investigate and respond
appropriately to complaints against accredited facilities.
++ TCT's processes and procedures for monitoring a HIT supplier
found out of compliance with TCT's program requirements.
++ TCT's capacity to report deficiencies to the surveyed facilities
and respond to the facility's plan of correction in a timely manner.
++ TCT's capacity to provide CMS with electronic data and reports
necessary for effective assessment and interpretation of the
organization's survey process.
++ The adequacy of TCT's staff and other resources, and its
financial viability.
++ TCT's capacity to adequately fund required surveys.
++ TCT's policies with respect to whether surveys are announced or
unannounced, to ensure that surveys are unannounced.
++ TCT's agreement to provide CMS with a copy of the most current
accreditation survey together with any other information related to the
survey as CMS may require (including corrective action plans).
++ TCT's policies and procedures to avoid conflicts of interest,
including the appearance of conflicts of interest, involving
individuals who conduct surveys, audits or participate in accreditation
decisions.
++ TCT's agreement or policies for voluntary and involuntary
termination of HIT suppliers.
++ TCT's agreement or policies for voluntary and involuntary
termination of the HIT AO program.
IV. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public comments, we normally receive
on Federal Register documents, we are not able to acknowledge or
respond to them individually. We will consider all comments we receive
by the date and time specified in the DATES section of this preamble,
and, when we proceed with a subsequent document, we will respond to the
comments in the preamble to that document.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Trenesha Fultz-Mimms, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2024-09172 Filed 4-26-24; 8:45 am]
BILLING CODE 4120-01-P